NPI: 1801197256 · SANTA FE, NM 87505 · Clinical Medical Laboratory · NPI assigned 11/16/2010
Authorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
| Authorized Official | WILLIAMS, KIMBERLY (VP) |
| NPI Enumeration Date | 11/16/2010 |
Other providers sharing the same authorized official: WILLIAMS, KIMBERLY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 68,380 | $1.13M |
| 2019 | 73,117 | $1.75M |
| 2020 | 65,811 | $999K |
| 2021 | 51,729 | $884K |
| 2022 | 36,134 | $722K |
| 2023 | 28,493 | $713K |
| 2024 | 15,498 | $488K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 7,766 | 7,502 | $1.06M |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 2,754 | 2,671 | $644K |
| 88267 | 6,852 | 6,346 | $597K | |
| 84702 | 79,173 | 73,116 | $596K | |
| 82105 | 60,959 | 57,580 | $523K | |
| 82677 | 35,570 | 33,409 | $489K | |
| 88235 | 7,732 | 7,194 | $483K | |
| 84163 | 51,165 | 48,295 | $433K | |
| 88262 | 5,068 | 4,871 | $333K | |
| 86336 | 35,207 | 33,096 | $320K | |
| 88230 | 4,149 | 3,960 | $230K | |
| 88271 | 5,237 | 4,703 | $217K | |
| 88233 | 2,080 | 2,011 | $157K | |
| 81243 | 2,012 | 1,930 | $143K | |
| 88274 | 5,035 | 4,439 | $142K | |
| 88280 | 6,800 | 6,329 | $93K | |
| 88285 | 7,182 | 6,692 | $64K | |
| 81329 | 1,806 | 1,726 | $62K | |
| 82106 | 4,190 | 3,939 | $43K | |
| 81508 | 761 | 761 | $19K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 162 | 132 | $7K |
| 81401 | 41 | 39 | $7K | |
| 81511 | 117 | 117 | $5K | |
| 82013 | 865 | 794 | $5K | |
| 81229 | 193 | 187 | $5K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 115 | 110 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 32 | 29 | $2K |
| 36415 | Collection of venous blood by venipuncture | 1,015 | 982 | $1K |
| 87496 | 28 | 25 | $393.78 | |
| 81422 | 705 | 704 | $0.00 | |
| 99080 | 43 | 20 | $0.00 | |
| 81479 | Unlisted molecular pathology procedure | 536 | 535 | $0.00 |
| 96040 | 3,812 | 3,799 | $0.00 |